A Safe and Effective Approach to Gene Therapy

1
Cyto Pulse Sciences, Inc
A Medical Device and Treatment Development Company
25 June 2009
Instruments - Therapeutic Production Medical
Devices - DNA Vaccine Delivery
0621
2
Business Areas

• Instruments - Produce/Discover Therapeutics
• More than 40 Revenue Producing Licenses in Place
• Growing 40 per year
• Development Stage Medical Devices
• Deliver DNA/RNA Therapy
• Focus on cancer treatment and infectious diseases
• Clinical trials in progress
• Looking for partners to license

3
Hybrimune mAb Discovery InstrumentA number have
multiple licenses
Others in negotiation
4
Large Volume Cyto LVT-PTherapeutic Production
Instrument

• Closed sterile transfection system
• One 23 minute run produces product for 50k to
  100k human vaccine doses
• Vaccine production begins fall 2009
• Partner-AlphaVax Human Vaccines
• Novartis licenses CMV vaccine(press release 28
  Dec 2008)
• 20 million payment to AlphaVax
• Expected to enter Phase II in 2009

5
Derma Vax DNA Intradermal Delivery Cancer
Immunotherapy Medical Device

• Delivery Process
• Insert therapetic into skin using hypodermic
  needle
• Insert electrode into skin (2 mm)
• Apply voltage waveform (1/3 second)
• Waveform generator
• Touch screen user input
• Computer controlled
• Compliance Certified
• Electrode single use, sterile and disposable

6
Clinical Trials - Phase I

• 8 Cancer academic collaboratorsLymphoma,
  prostate, colorectal, breast
• 15 Infectious Disease academic collaboratorsHIV,
  Flu, Hep B, Hep C

Need Partners
7
Easy Vax DNA Epidermal DeliveryProphylactic
(infectious diseases)
System Operation

• Load coated array
• Insert array into skin
• DNA comes off needles
• Electric field delivers DNA

battery

• Sponsor NIAID 5 million
• Dengue 4 serotype vaccine
• Tested with smallpox (mice)
• Human tolerability trial

8
Easy Vax Current StatusMice and Monkeys -
dengue
Monkey Response needs optimization
9
Cyto Pulse Sciences, Inc.

• Incorporated 1995
• Maryland C Corp
• 15 Employees
• Engineers
• Biologists
• 94 approved vendors
• Products in production
• Quality Design Control System
• FDA CFR-820
• EU MDD
• No institutional investors

Headquarters Glen Burnie, MD, USAStockholm,
Sweden Tokyo, Japan
10
Leadership Team

• Management
• Richard Walters, BSE, MSEE, MBA, Founder CEO
• Alan King, DVM, PhD, Founder VP
• Derin Walters, BSE, MBA VP Asian Operations
• John B. Burke, MBA, CPA CFO
• Anna-Karin Roos, PhD Mgr EU Operations
• Board of Directors
• Richard Walters Chairman
• Harold Chappelear, BS Pharma (former EVP Upjohn)
• Daniel Rak, JD
• Stephen Schimpff, MD (former CEO UMMC)
• Scientific Advisory Board (SAB)
• Stephen Schimpff, MD Chairman
• Judith Karp, MD, Oncology JHU Med School
• Ruben Mezrich, MD, PhD EE, Radiology UM Med
  School
• Carol Tacket, MD, UM Center for Vaccine Dev UM
  Med School

11

• Thank you to Larta for the Opportunity
• Will be around conference and available for
  discussions